Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome. - Wikidata - awgldk - TriplyDB

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.

http://www.wikidata.org/entity/Q33389149

about

Acute promyelocytic leukemia: where did we start, where are we now, and the future Acute Promyelocytic Leukemia (APL): Comparison Between Children and Adults Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Le Curing all patients with acute promyelocytic leukemia: are we there yet?Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy.Clinical study on prospective efficacy of all-trans Acid, realgar-indigo naturalis formula combined with chemotherapy as maintenance treatment of acute promyelocytic leukemia Single-nucleotide polymorphism array-based karyotyping of acute promyelocytic leukemia.ATO/ATRA/anthracycline-chemotherapy sequential consolidation achieves long-term efficacy in primary acute promyelocytic leukemia.Acute myeloid leukemia, version 2.2013.SNP array analysis of acute promyelocytic leukemia may be of prognostic relevance and identifies a potential high risk group with recurrent deletions on chromosomal subband 1q31.3.Therapy-related acute promyelocytic leukemia: observations relating to APL pathogenesis and therapy.Presenting features and treatment outcome of acute promyelocytic leukemia arising after multiple sclerosis.Clinical characteristics, outcome and early induction deaths in patients with acute promyelocytic leukaemia: a five-year experience at a tertiary care centre High-Risk Microgranular Acute Promyelocytic Leukemia with a Five-Way Complex Translocation Involving PML-RARA Real-life experience of a brief arsenic trioxide-based consolidation chemotherapy in the management of acute promyelocytic leukemia: favorable outcomes with limited anthracycline exposure and shorter consolidation therapy Epidemiology and treatment of acute promyelocytic leukemia in latin america Acute promyelocytic leukemia: an experience on 95 greek patients treated in the all-trans-retinoic Acid era The differentiation syndrome in patients with acute promyelocytic leukemia: experience of the pethema group and review of the literature Newly diagnosed acute promyelocytic leukemia Results of the APML3 trial incorporating all-trans-retinoic acid and idarubicin in both induction and consolidation as initial therapy for patients with acute promyelocytic leukemia Budgetary impact of treating acute promyelocytic leukemia patients with first-line arsenic trioxide and retinoic acid from an Italian payer perspective.Retinoic acid-induced differentiation increases the rate of oxygen consumption and enhances the spare respiratory capacity of mitochondria in SH-SY5Y cells.All-Trans Retinoic Acid plus Arsenic Trioxide versus All-Trans Retinoic Acid plus Chemotherapy for Newly Diagnosed Acute Promyelocytic Leukemia: A Meta-Analysis.Consolidation therapy of arsenic trioxide alternated with chemotherapy achieves remarkable efficacy in newly diagnosed acute promyelocytic leukemia.Outcome of elderly patients with acute promyelocytic leukemia: results of the German Acute Myeloid Leukemia Cooperative Group.Emerging new approaches for the treatment of acute promyelocytic leukemia.A tale of two approaches: complementary mechanisms of cytotoxic and targeted therapy resistance may inform next-generation cancer treatments The results of the International Consortium on Acute Promyelocytic Leukemia: a 'proof of concept' of networking as a strategy to improve the outcome of treatment of hematological malignancies in developing countries Current routine practice and clinico-pathological characteristics associated with acute promyelocytic leukemia in Korea.Azacitidine might be beneficial in a subgroup of older AML patients compared to intensive chemotherapy: a single centre retrospective study of 227 consecutive patients.Early death rate in acute promyelocytic leukemia remains high despite all-trans retinoic acid Cost-Effectiveness Analysis of Treating Acute Promyelocytic Leukemia Patients With Arsenic Trioxide and Retinoic Acid in the United States.Co-expression of t(15;17) and t(8;21) in a Case of Acute Promyelocytic Leukemia: Review of the Literature How I treat children and adolescents with acute promyelocytic leukaemia.Bayesian network meta-analysis comparing five contemporary treatment strategies for newly diagnosed acute promyelocytic leukaemia.Guidelines on the diagnosis and treatment for acute promyelocytic leukemia: Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular Guidelines Project: Associação Médica Brasileira - 2013 Molecular and hematologic relapses in adult patients with acute promyelocytic leukemia: a cohort study.Integrating microRNA and mRNA expression profiles of acute promyelocytic leukemia cells to explore the occurrence mechanisms of differentiation syndrome.Retinoic acid and arsenic trioxide in the treatment of acute promyelocytic leukemia: current perspectives.Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia

P2860

Q26830385-9631F3D7-CC4E-4208-9DF9-D7E208CC45A2 Q27009433-ED40BFBA-6B4C-401F-B4EA-5D6E6E6EC1B5 Q27853031-59690F0C-7725-487F-9251-3103EEB17830 Q33613426-5963DF13-F553-40A1-98E6-A517E1D37106 Q33631350-6E0743DF-0C7C-4379-9B5A-7CA5761C197F Q33746130-4CE4CE64-D77D-4744-9007-1D8693BFCA09 Q33800102-02C875E6-9A5B-4A1B-B304-5A491495295D Q34046794-5F14FA85-ED7D-4B9A-9234-6A0A17653AC7 Q34165330-B9630105-0A87-4D97-838A-60BBBB55EB00 Q34226368-54210996-4D3E-4ED1-8615-53EC9C2FAF68 Q34227027-B6589922-7CF0-435D-91CA-6626F2A03B25 Q34750640-F3F66C2E-8DBD-4C1F-8D54-7E290C59E915 Q34953881-F42D83A9-4098-405D-9A40-26CDDE3D79FB Q35062053-FDBE8CA6-263C-4DBC-AC51-767E369C83A6 Q35537150-C08EAB0F-7050-42C0-9618-6493C0C5F9FC Q35560268-54AC2EB0-ADBC-4ED9-9648-F0440333F8B6 Q35640734-6BA3242C-B8D5-47D4-B971-B705FE74A277 Q35640755-EA14C1CF-5D0A-44D7-9A62-0368C9AF1D9B Q35640773-431A45A2-995C-45EF-A6FA-F0AFF186D3D5 Q35717816-A9BCB339-C36B-4A30-9451-942E05158CB9 Q35743980-9A6CA35E-8698-4848-82FB-EEF2CC27EF05 Q35975751-671DE020-39E1-43C6-82C2-6D4272972968 Q36070904-EFB3DED3-31EC-4B6D-A932-A3CD7DE260A9 Q36303245-A469B773-C5A2-41BC-8164-F5868AAC54FF Q36508333-50EE0BA6-2903-48A9-AEE5-3AFA7DA7E38D Q36612619-8E7D7512-6EBE-43EE-BD41-71F1765C6124 Q36740744-DCEA268E-980D-4B08-ADA9-0E2664B7CF0C Q36753253-13D3F2B0-9370-4949-AD0E-92AB88EE54EF Q36761829-5D3CAA7E-E8DE-4F98-A40A-32C602641A51 Q36805563-D63B475B-2DA8-4ED3-A23E-23C6D671BCAC Q37216174-AF597BBD-E8AB-4EDF-858F-88F34E2D8921 Q37267500-3ABB308E-481A-414C-A441-910B132B08AE Q37418961-90EEF141-D441-41F8-9089-4252D93FBA93 Q37451376-16C42745-5E85-4383-A818-3E1BB037847A Q37565126-3B51D262-5DF6-474E-9114-D52AAF137F36 Q37628630-246F5869-26BB-4AE1-9DE4-A81510DBDCDA Q37683361-F5827303-4B19-4254-8D81-66B5D92F4200 Q37687421-1D7D8DC9-7424-4FF2-81CC-E8EC0E432A06 Q37712353-AF218F97-08F4-468E-B954-846DF103106C Q37899041-69A124B4-4413-4142-AE00-321DAF6B1049

P2860

Risk-adapted treatment of acute promyelocytic leukemia based on all-trans retinoic acid and anthracycline with addition of cytarabine in consolidation therapy for high-risk patients: further improvements in treatment outcome.

http://www.wikidata.org/entity/Q33389149

description

2010 nî lūn-bûn

@nan

2010 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年学术文章

@wuu

2010年学术文章

@zh-cn

2010年学术文章

@zh-hans

2010年学术文章

@zh-my

2010年学术文章

@zh-sg

2010年學術文章

@yue

name

Risk-adapted treatment of acut ...... ovements in treatment outcome.

@ast

Risk-adapted treatment of acut ...... ovements in treatment outcome.

@en

type

label

Risk-adapted treatment of acut ...... ovements in treatment outcome.

@ast

Risk-adapted treatment of acut ...... ovements in treatment outcome.

@en

prefLabel

Risk-adapted treatment of acut ...... ovements in treatment outcome.

@ast

Risk-adapted treatment of acut ...... ovements in treatment outcome.

@en

P1433

Q33389149-25C8672D-2779-4FD0-8020-0AA444D0FC02

P1476

Q33389149-CFAC1842-2077-4EB8-BB79-4F83EB719C0D

P2093

Q33389149-002387CE-25C5-4AB7-B364-7C443188D147

Q33389149-09A81D44-CC1F-458F-96B9-1EE1CC899634

Q33389149-0A4423E5-18E6-4BB4-A448-2B08179936AB

Q33389149-0C4F9954-0E4B-4CC4-802C-7E0845BEE32D

Q33389149-1B0EB152-6831-4032-856D-49E4B1F12178

Q33389149-20CFFE69-865C-4502-A24B-F8027DE0DCFC

Q33389149-2D52FFA6-D5BC-44B9-ACCA-936B3FBC6E47

Q33389149-44F44C5A-6EC6-4140-A024-97EA146CF203

Q33389149-4D8379C0-ABE5-4E8E-9634-1D686D6FDA7C

Q33389149-5748C752-A4DA-4F30-A4E7-5C835261882B

P304

Q33389149-E3AE69E9-F604-4870-92C3-F89462693D23

P31

Q33389149-CBB38493-3518-4A46-A8B1-1B3A9F87700B

P356

Q33389149-D1F704EB-1276-4AA5-B070-454BD7C43CBD

P407

Q33389149-D0C51AC5-9C87-4A69-AE50-B9B30BD5B0C8

P433

Q33389149-137CBB6B-857A-4E2D-99B2-AE3CC0268A4D

P478

Q33389149-1B81AB1D-6FA5-4FF5-B44B-393FCDFAFAF1

P50

Q33389149-034A674E-A122-4111-B668-1819B5FF919B

Q33389149-41D3C8C9-423D-42B3-8548-86F539DBB593

Q33389149-505F68A0-4FDD-4851-A25B-34924A06C2C1

P577

Q33389149-5427D309-3735-4982-B547-C923063997A3

P698

Q33389149-6AFF508B-028B-47B2-B1A7-3578F6F8F86B

P921

Q33389149-DDF8E675-6A74-40A3-B11F-8898148E0C49

P356

BLOOD-2010-01-266007

P1433

P1476

Risk-adapted treatment of acut ...... ovements in treatment outcome.

@en

P2093

Alexandra Holowiecka

http://www.w3.org/2001/XMLSchema#string

Chelo Rayón

http://www.w3.org/2001/XMLSchema#string

Concha Rivas

http://www.w3.org/2001/XMLSchema#string

Elena de Lisa

http://www.w3.org/2001/XMLSchema#string

Félix Manso

http://www.w3.org/2001/XMLSchema#string

Gert Ossenkoppele

http://www.w3.org/2001/XMLSchema#string

Gustavo Milone

http://www.w3.org/2001/XMLSchema#string

Isabel Krsnik

http://www.w3.org/2001/XMLSchema#string

Joaquín Díaz-Mediavilla

http://www.w3.org/2001/XMLSchema#string

José D González

http://www.w3.org/2001/XMLSchema#string

P304

5137-5146

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1182/BLOOD-2010-01-266007

http://www.w3.org/2001/XMLSchema#string

P407

P433

25

http://www.w3.org/2001/XMLSchema#string

P478

115

http://www.w3.org/2001/XMLSchema#string

P50

Javier de la Serna

P577

2010-04-14T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

20393132

http://www.w3.org/2001/XMLSchema#string

P921